Latest Healthcare News

Genetic Signatures says its existing directors will resign if BCAL nominees become a majority after the 28 October EGM. The company is also demanding clarity on whether BCAL intends to merge with GSS, pointing to the stark difference between the two companies’ cash runways.

Ramsay Health Care has cleared the first legal step towards distributing its 52.79% stake in Ramsay Générale de Santé to shareholders. The proposed demerger now goes to consecutive shareholder meetings on 24 November, backed by the board and Deloitte’s independent expert.

Vitura Health grew FY2026 revenue 6% to $131.2 million, but a sharp margin squeeze pushed the ASX-listed digital health company into a $4.4 million statutory loss. With ANZ debt classified as current and a potential $6 million FY2027 revenue hit from changed Bupa referrals, the promised turnaround faces a demanding test.

Medical Developments International CEO Brent MacGregor is stepping down after six years, with CFO Anita James taking over as interim CEO from 15 October. The board has begun searching for a permanent successor as MacGregor prepares to return to North America.

Promisia Healthcare has maintained group care occupancy at 96%, above its 95% target, while completing the Chatswood acquisition and preparing to potentially accelerate full ownership of Golden View Village. FY27 underlying EBITDAF guidance of at least $8.0 million remains unchanged for the existing portfolio, with updated guidance due in November.

Anatara Lifesciences will manufacture an approximately 10,000-capsule demonstration batch of its AOC anti-obesity compound after deciding further pre-clinical work and an immediate clinical trial are not required. The company ended September with $551,000 in cash, helped by a $318,402 R&D tax rebate.

Orthocell says Remplir was placed successfully in five complex robotic prostatectomy cases, with no device-related complications reported over approximately 12 months. The preliminary results will guide a larger prospective trial ahead of a planned US expansion for the nerve repair product.

Vitura Health has opened FY2027 with a sharp improvement in EBITDA and lower operating costs, while revenue growth continued across its digital health businesses. The figures are unaudited, and the company still needs to prove that the improvement can survive the wind-down of Bupa-related telehealth volumes.

Acrux says the FDA has confirmed the evidence package required to take its female testosterone spray into Phase III trials for postmenopausal women with HSDD. The agency also indicated the company may apply for three years of data exclusivity if the product reaches submission.

Firebrick Pharma has raised approximately $732,000 from strategic investors, with its Philippines licensing partner investing $631,750 to lift its holding above 10%. The funding will support US retail production, a Singapore product launch and working capital.

Ryman Healthcare’s retirement village resales reached an eight-quarter high in the second quarter, while aged care occupancy climbed to 94%. The operating update also shows new-sales inventory continuing to decline as the company positions for stronger recurring earnings.

Medical Developments International returned to EBIT profitability in FY26 as Penthrox volumes strengthened across Australian hospitals and Europe. The company now faces the less glamorous test of converting regulatory progress into repeatable demand while absorbing weaker Respiratory sales and new amortisation costs.